Leukotriene E4, 24 Hour Urine
| Abbrev Code: | TLTE4 | ||
| Order Code: | LAB8251 | Order Name: | Leukotriene E4, 24 Hour Urine |
| Methodology: | Leukotriene: Liquid chromatography/Tandem mass spectrometry (LC/MS/MS)
Creatinine: Enzymatic colorimetric assay |
||
| CPT Codes: | 82542 x1, 82542 x1 | ||
| Test Includes: | Leukotriene, Urine; Creatinine, Urine | ||
| Turnaround Time: | Specimens are sent to the reference laboratory Mon-Fri; tests are performed Mon and Thurs. Results are reported within 2-6 days. | ||
| Compliance: | This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration. |
||
Collection Instructions
| Specimen: | 24 hour urine collection is the preferred specimen; a random specimen is accepted (order LAB6543). |
| Optimal Volume: | Submit entire collection; analysis requires 5 mL. |
| Minimum\Peds Volume: | 5 mL |
| Container: | 3 L plastic jug |
| Collection Instructions: | Collect 24 hour urine without preservatives. Store specimen refrigerated during collection. |
Processing and Shipping
| Specimen Processing: | Aliquot 5 mL. Store frozen. |
| Shipping Instructions: | Ship frozen. |
| Stability: | 24 hour at room temperature; 7 days refrigerated; 28 days frozen (preferred). |
| Test Performed at or Referral Lab | Lab Sendouts (Mayo Medical Laboratories) |
| Referral Lab number: | TLTE4 |
Interpretive
| Reference Range: | Leukotriene E4: ≤104 pg/mg creatinine
|
||||||
| Use: | An aid to evaluate patients suspected of having systemic mastocytosis using 24 hour urine collections. Systemic mastocytosis (SM) is a heterogenous disorder, including N-methylhistamine (NMH) and 11 beta-prostaglandin F2 alpha (23BPG) analysis along with this test provides a clinical sensitivity greater than 90% and specificity greater than 60%.
Elevated urinary leukotriene E4 (LTE4) concentrations >104 pg/mg creatinine are consistent with the diagnosis of systemic mast cell disease when combined with clinical signs and symptoms. Pharmacological treatment with 5-lipoxygenase inhibitors or leukotriene receptor antagonists has been shown to decrease production of LTE4. |
Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
[email protected] for TestID: 6973"